local_hospital

Neurologia Slaska Centrum Medyczne

Address
lock Available on a paid plan

Immune System Diseases at Neurologia Slaska Centrum Medyczne

Clinical research here is strongly focused on immune system diseases, especially generalized myasthenia gravis and related antibody-positive and antibody-negative forms. These studies are designed to test new therapies, compare treatment options, and better understand long-term safety and symptom control.

  • Studies in generalized myasthenia gravis are evaluating whether new treatments can improve daily functioning and reduce disease burden.
  • Research also includes ocular myasthenia gravis and pediatric cases, broadening care across age groups and disease subtypes.
  • Several trials assess the safety and effectiveness of emerging immune-targeted therapies compared with placebo or established treatment approaches.
  • Additional work looks at chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, with a focus on maintaining response and improving mobility.

Overall, this site is a notable center for advancing treatment options in antibody-mediated neuromuscular conditions and other immune-related disorders.

Nervous System Diseases Research

The site also supports a broad portfolio in nervous system diseases, with trials spanning movement disorders, dementias, and neurodevelopmental conditions. The main goal is to explore better ways to slow progression, ease symptoms, and improve quality of life.

  • Parkinson disease studies are examining whether new therapies can improve motor fluctuations and reduce time spent “off” medication benefit.
  • Research in multiple sclerosis, including relapsing forms, aims to lower relapse risk and support long-term disease control.
  • Trials in progressive supranuclear palsy, multiple system atrophy, and Alzheimer’s disease are focused on slowing clinical decline and testing novel treatment strategies.
  • Tourette syndrome studies are evaluating medicines intended to help manage tic severity across children, adolescents, and adults.

These studies reflect a strong neurology research environment in Katowice, with attention to both common and rare brain disorders.

Musculoskeletal Diseases and Related Neuromuscular Care

Within musculoskeletal diseases, the research emphasis overlaps with neuromuscular function and disability caused by chronic inflammatory conditions. The trials are mainly aimed at improving strength, preserving function, and evaluating how well treatments work in everyday life.

  • Studies in chronic inflammatory demyelinating polyneuropathy are assessing whether new approaches can help maintain clinical response and support nerve-related function.
  • Research in multifocal motor neuropathy is looking at treatment effectiveness and tolerability in people with weakness and motor impairment.
  • Several projects compare emerging therapies with established immunoglobulin-based care to determine whether outcomes can be improved.
  • The overall focus is on better symptom control, longer-lasting benefit, and more practical treatment options for patients.

At Neurologia Slaska Centrum Medyczne, this area complements the broader neurology portfolio by addressing disorders that affect movement and physical independence.

Site Overview

assignment
34
connected trials
corporate_fare
18
sponsors
science
46
IMPs

Activity Indicator

Last 6 months

2
Trials started
-67% vs previous period.
6
Trials started 6–12 months ago
34
Total trials linked
Highly Active
trending_downDeclining-67%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 therapeutic areas and 15 of 46 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 46 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
19
Sponsors (total)
18
Active sponsors
12

Sponsor Network

Top 12 by active trials.

lock +11 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
34
Outperforms 91% of sites
public
Therapeutic diversity
3areas
Outperforms 70% of sites
groups
Sponsor diversity
18sponsors
Outperforms 90% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Neurologia Slaska Centrum Medyczne

lock Showing 1 of 34 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbHPhase IIRecruitingNov 2025

IMP list

lock Showing 1 of 46 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Efgartigimod Alfa6Unknown2021-10-272026-03-13

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.